Showing results (4091-4100 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|June 14, 2025
First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancerRyan J Sullivan, Oladapo O Yeku, Deanna Teoh, et al.
The Oncologist|June 12, 2025
Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective studyYu-Chao Hou, Jin-Kai Feng, Kang Wang, et al.
The Oncologist|June 16, 2025
Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trialTrish Millard, Lena M Turkheimer, Jenna Schlefman, et al.
The Oncologist|June 10, 2025
Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions induced by immune checkpoint inhibitorsZiliang Zheng, Zhu Shen
The Oncologist|June 23, 2025
Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypesGyöngyi Munkácsy, Libero Santarpia, Balázs Győrffy
The Oncologist|June 24, 2025
Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancerLi Sun, Zhimin Gong, Lei Wang, et al.
The Oncologist|June 21, 2025
The prognostic role of Geriatric 8 in patients with cancer: a meta-analysis and systematic reviewRunzhi Chen, Dongmei Yang, Mengxing Tian, et al.
The Oncologist|June 20, 2025
Clinical features and prognostic factors of intravascular large B-cell lymphoma: a cohort study of 20 patients from 2018 to 2024Yaqing Li, Suxiao Li, Xiyang Liu, et al.
The Oncologist|June 19, 2025
Prolonged response to PIK3CA inhibition in an advanced hormone-positive breast cancer patient with 3 mutations in the alpha subunit of PI-3 kinaseRotem Merose, Raya Leibowitz
The Oncologist|June 23, 2025
Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitorsZhen-Xin Zeng, Hua-Chun Song, Yi-Nan Li, et al.
Pageof 571